Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more
Royalty Pharma Plc (RPRX) - Net Assets
Latest net assets as of December 2025: $9.71 Billion USD
Based on the latest financial reports, Royalty Pharma Plc (RPRX) has net assets worth $9.71 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.62 Billion) and total liabilities ($9.91 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.71 Billion |
| % of Total Assets | 49.51% |
| Annual Growth Rate | 25.84% |
| 5-Year Change | -5.21% |
| 10-Year Change | 117.82% |
| Growth Volatility | 2064.72 |
Royalty Pharma Plc - Net Assets Trend (2000–2025)
This chart illustrates how Royalty Pharma Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Royalty Pharma Plc (2000–2025)
The table below shows the annual net assets of Royalty Pharma Plc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.71 Billion | -6.07% |
| 2024-12-31 | $10.34 Billion | +2.56% |
| 2023-12-31 | $10.08 Billion | +5.87% |
| 2022-12-31 | $9.53 Billion | -7.06% |
| 2021-12-31 | $10.25 Billion | -31.55% |
| 2020-12-31 | $14.97 Billion | +143.80% |
| 2019-12-31 | $6.14 Billion | +34.92% |
| 2018-12-31 | $4.55 Billion | +1.85% |
| 2017-12-31 | $4.47 Billion | +0.21% |
| 2016-12-31 | $4.46 Billion | -5.05% |
| 2015-12-31 | $4.70 Billion | +10571.11% |
| 2014-12-31 | $44.02 Million | -41.64% |
| 2013-12-31 | $75.42 Million | +227.45% |
| 2012-12-31 | $23.03 Million | +393.66% |
| 2011-12-31 | $4.67 Million | +47.33% |
| 2010-12-31 | $3.17 Million | +463.52% |
| 2009-12-31 | $562.00K | -96.40% |
| 2008-12-31 | $15.61 Million | -35.10% |
| 2007-12-31 | $24.06 Million | +534.83% |
| 2006-12-31 | $3.79 Million | -77.65% |
| 2005-12-31 | $16.95 Million | +182.96% |
| 2004-12-31 | $5.99 Million | -74.49% |
| 2003-12-31 | $23.49 Million | -12.53% |
| 2002-12-31 | $26.85 Million | -12.16% |
| 2001-12-31 | $30.57 Million | -1.58% |
| 2000-12-31 | $31.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Royalty Pharma Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 235631800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.36 Billion | 36.38% |
| Common Stock | $106.00K | 0.00% |
| Other Components | $4.12 Billion | 63.62% |
| Total Equity | $6.48 Billion | 100.00% |
Royalty Pharma Plc Competitors by Market Cap
The table below lists competitors of Royalty Pharma Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hannover Rück SE
PINK:HVRRF
|
$18.13 Billion |
|
Henkel AG & Co. KGaA vz. (Pref Shares)
XETRA:HEN3
|
$18.16 Billion |
|
Aviva plc
PINK:AIVAF
|
$18.17 Billion |
|
Charter Communications Inc
NASDAQ:CHTR
|
$18.18 Billion |
|
Northern Star Resources Limited
F:NS7
|
$18.08 Billion |
|
Vodafone Group PLC
PINK:VODPF
|
$18.08 Billion |
|
Credicorp Ltd
NYSE:BAP
|
$18.04 Billion |
|
Southwest Airlines Company
NYSE:LUV
|
$18.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Royalty Pharma Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,946,581,000 to 6,476,900,000, a change of -469,681,000 (-6.8%).
- Net income of 770,947,000 contributed positively to equity growth.
- Dividend payments of 378,253,000 reduced retained earnings.
- Share repurchases of 1,227,383,000 reduced equity.
- Other factors increased equity by 365,008,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $770.95 Million | +11.9% |
| Dividends Paid | $378.25 Million | -5.84% |
| Share Repurchases | $1.23 Billion | -18.95% |
| Other Changes | $365.01 Million | +5.64% |
| Total Change | $- | -6.76% |
Book Value vs Market Value Analysis
This analysis compares Royalty Pharma Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 525.79x to 3.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.09 | $46.11 | x |
| 2001-12-31 | $0.09 | $46.11 | x |
| 2002-12-31 | $0.08 | $46.11 | x |
| 2003-12-31 | $0.07 | $46.11 | x |
| 2004-12-31 | $0.02 | $46.11 | x |
| 2005-12-31 | $0.05 | $46.11 | x |
| 2006-12-31 | $0.01 | $46.11 | x |
| 2007-12-31 | $0.07 | $46.11 | x |
| 2008-12-31 | $0.04 | $46.11 | x |
| 2009-12-31 | $0.00 | $46.11 | x |
| 2010-12-31 | $0.01 | $46.11 | x |
| 2011-12-31 | $0.01 | $46.11 | x |
| 2012-12-31 | $0.07 | $46.11 | x |
| 2013-12-31 | $0.21 | $46.11 | x |
| 2014-12-31 | $0.12 | $46.11 | x |
| 2015-12-31 | $7.70 | $46.11 | x |
| 2016-12-31 | $7.32 | $46.11 | x |
| 2017-12-31 | $12.59 | $46.11 | x |
| 2018-12-31 | $12.67 | $46.11 | x |
| 2019-12-31 | $17.24 | $46.11 | x |
| 2020-12-31 | $26.36 | $46.11 | x |
| 2021-12-31 | $13.93 | $46.11 | x |
| 2022-12-31 | $12.85 | $46.11 | x |
| 2023-12-31 | $10.83 | $46.11 | x |
| 2024-12-31 | $11.69 | $46.11 | x |
| 2025-12-31 | $11.57 | $46.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Royalty Pharma Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.90%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.42%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 3.03x
- Recent ROE (11.90%) is above the historical average (9.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -73.91% | 0.00% | 0.00x | 1.07x | $-36.94 Million |
| 2015 | 12.43% | 35.19% | 0.15x | 2.31x | $113.74 Million |
| 2016 | 12.73% | 30.14% | 0.18x | 2.36x | $121.34 Million |
| 2017 | 27.13% | 75.72% | 0.14x | 2.55x | $763.97 Million |
| 2018 | 30.70% | 76.76% | 0.16x | 2.53x | $928.91 Million |
| 2019 | 38.47% | 129.45% | 0.15x | 2.04x | $1.74 Billion |
| 2020 | 9.85% | 45.94% | 0.10x | 2.13x | $-14.56 Million |
| 2021 | 10.73% | 27.07% | 0.13x | 3.03x | $42.07 Million |
| 2022 | 0.76% | 1.91% | 0.13x | 2.99x | $-519.98 Million |
| 2023 | 17.39% | 48.20% | 0.14x | 2.51x | $482.18 Million |
| 2024 | 12.37% | 37.95% | 0.12x | 2.62x | $164.32 Million |
| 2025 | 11.90% | 32.42% | 0.12x | 3.03x | $123.26 Million |
Industry Comparison
This section compares Royalty Pharma Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Royalty Pharma Plc (RPRX) | $9.71 Billion | -73.91% | 1.02x | $18.10 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |